Immunotherapy for Tauopathies
- 8 July 2011
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 45 (3) , 690-695
Abstract
Pathological tau protein is found in Alzheimer's disease and related tauopathies. The protein is hyperphosphorylated and/or mutated which leads to aggregation and neurotoxicity. Because cognitive functions correlate well with the degree of tau pathology, clearing these aggregates is a promising therapeutic approach. Studies pioneered by our laboratory and confirmed by others have shown that both active and passive immunizations targeting disease-related tau epitopes successfully reduce tau aggregates in vivo and slow or prevent behavioral impairments in mouse models of tauopathy. Here, we summarize recent advances in this new field.Keywords
This publication has 52 references indexed in Scilit:
- Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brainJournal of Neurochemistry, 2011
- Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-β ImmunotherapyJournal of Neuroscience, 2011
- Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)Proceedings of the National Academy of Sciences, 2010
- BapineuzumabExpert Opinion on Biological Therapy, 2010
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?Nature Reviews Neurology, 2010
- Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau PathologyThe Journal of Neuroscience, 2009
- Transmission and spreading of tauopathy in transgenic mouse brainNature Cell Biology, 2009
- Propagation of Tau Misfolding from the Outside to the Inside of a CellJournal of Biological Chemistry, 2009
- Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s diseaseActa Neuropathologica, 2009
- Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic miceProceedings of the National Academy of Sciences, 2007